Regeneron Pharmaceuticals has entered the radiopharmaceutical sector through a collaboration with Telix Pharmaceuticals, aiming to develop treatments across multiple solid tumor indications. The agreement involves the use of Telix’s radiopharmaceutical platform in combination with Regeneron’s antibody portfolio, including bispecific antibodies.
According to the terms disclosed, Regeneron will provide an upfront payment of $40 million to initiate work on four programs. The companies will share global development expenses and commercialization profits equally for these initial projects. Regeneron also retains the option to expand the collaboration by adding four more programs in exchange for an additional upfront payment, the amount of which has not been disclosed.
For individual programs, Telix may choose not to participate in cost-sharing. In such cases, it would instead be eligible to receive up to $535 million in development and commercial milestone payments per program, along with low double-digit royalties on net sales. If Regeneron exercises its option to expand to eight programs in total, Telix could receive up to approximately $4.3 billion in milestone payments. Alternatively, opting out of cost-sharing across the initial four programs could yield up to $2.1 billion in potential milestone revenue for Telix, assuming all targets are met.
The collaboration will focus on leveraging Regeneron’s existing antibody assets to address unspecified solid tumor targets. Telix will contribute its radiopharmaceutical manufacturing and development capabilities to advance these programs. In addition to therapeutics, the agreement also includes work on diagnostic products, with Telix leading commercialization efforts while Regeneron receives a defined share of profits.
John Lin, senior vice president of Oncology and Antibody Technology Research at Regeneron, said, “Targeted radiopharmaceuticals represent a rapidly emerging frontier in oncology and an exciting opportunity to bring new treatment options to patients.”
Israel Lowy, head of Regeneron’s oncology clinical development unit, indicated that the company may evaluate these radiopharmaceutical candidates both as standalone treatments and in combination with its immunotherapy portfolio, including Libtayo, particularly in areas such as lung cancer where unmet patient need remains high.
The partnership places Regeneron among several large pharmaceutical companies pursuing radiopharmaceutical strategies. Novartis currently has two marketed assets in this category: Lutathera, approved in 2018 for gastroenteropancreatic neuroendocrine tumors, and Pluvicto, approved in 2022 for metastatic castration-resistant prostate cancer. In 2025, Lutathera generated $816 million in revenue, reflecting 12% annual growth, while Pluvicto reached $1.99 billion, marking a 42% increase.
Other companies have also made investments in the field. Eli Lilly acquired Point Biopharma for $1.4 billion in 2023 and later entered additional partnerships with Aktis Oncology and Radionetics Oncology. Bristol Myers Squibb acquired RayzeBio for $4.1 billion, including its lead asset RYZ-101, although a Phase 3 trial experienced a pause due to supply constraints. AstraZeneca entered the space through its $2.4 billion acquisition of Fusion Pharmaceuticals in 2024.
Telix has expanded its capabilities through several acquisitions, including IsoTherapeutics, ARTMS, and RLS Radiopharmacies, as well as select assets from ImaginAb. The company has also reported promising early data for its therapeutic candidate TLX101 in a small brain cancer study, while some of its diagnostic candidates, including Pixclara and Zircaix, faced regulatory setbacks.
Christian Behrenbruch, Telix’s group CEO, stated that the collaboration reflects complementary capabilities and an opportunity to advance biologics-based radiopharmaceuticals, adding that the companies aim to develop next-generation precision treatments for difficult-to-treat cancers.
Regeneron–Telix Collaboration Overview
The agreement between Regeneron Pharmaceuticals and Telix Pharmaceuticals focuses on the discovery and development of targeted radiopharmaceutical therapies. Through this deal, Regeneron gains access to Telix’s specialized platforms for delivering radiation directly to tumor cells.
The collaboration is structured to balance risk and reward for both companies. It typically includes upfront payments, milestone-based incentives tied to development and regulatory achievements, and potential royalties on future sales. This kind of framework allows both sides to invest confidently while sharing the financial burden of advancing multiple programs simultaneously.
The inclusion of up to eight programs makes the deal particularly noteworthy. Rather than focusing on a single asset, the partnership creates a broad development platform that increases the probability of clinical and commercial success.
Technology Integration and Development Strategy
At the core of the agreement is the integration of two complementary technologies. One side contributes expertise in targeting mechanisms—such as antibodies or small molecules—while the other brings advanced capabilities in linking these agents with radioactive isotopes.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
